FIA
JBIO

FNY Investment Advisers’s Jade Biosciences JBIO Stock Holding History

FNY Investment Advisers’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,143
Closed -$198K – 728
2024
Q4 		$198K Buy
+2,143
New +$185K 0.1% 176

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
AI
Allostery Investments Stamford, Connecticut $7.85M AUM
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FNY Investment Advisers's JBIO Position: Q1 2025 in Review

FNY Investment Advisers sold out of Jade Biosciences (JBIO) in Q1 2025, closing a stake of 2,143 shares — an estimated $198K sold.

FNY Investment Advisers first reported a position in JBIO in Q4 2024 and held it in 1 quarter. The position peaked at $198K in Q4 2024. 78 funds tracked by Wall St. Rank hold JBIO as of Q1 2025.

  • FNY Investment Advisers reported no remaining Jade Biosciences position as of Q1 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 2,143 Jade Biosciences shares in Q1 2025, an estimated $198K.
  • FNY Investment Advisers first reported a position in Jade Biosciences in Q4 2024 and held it in 1 quarter.
  • FNY Investment Advisers's Jade Biosciences position peaked at $198K in Q4 2024.
  • 78 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2025.

Based on FNY Investment Advisers's 13F filing for Q1 2025, filed 17 Apr 2025.